Company
Headquarters: Seongnam-si, South Korea
CEO: Mr. Jeong Woo Cho Ph.D.
₩9.625 Trillion
KRW as of Jan. 1, 2026
US$6.67 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | ₩675.41 B |
| EBITDA | ₩178.80 B |
| Gross Profit TTM | ₩641.58 B |
| Profit Margin | 47.45% |
| Operating Margin | 36.57% |
| Quarterly Revenue Growth | 40.40% |
SK Biopharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: KRX: 326030